Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:PLXP

PLx Pharma - PLXP Stock Forecast, Price & News

$0.35
-0.01 (-2.78%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.34
$0.37
50-Day Range
$0.33
$0.65
52-Week Range
$0.30
$10.53
Volume
104,500 shs
Average Volume
405,194 shs
Market Capitalization
$10.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

PLx Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
3,328.6% Upside
$12.00 Price Target
Short Interest
Healthy
0.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.81) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

610th out of 1,044 stocks

Pharmaceutical Preparations Industry

292nd out of 510 stocks

PLXP stock logo

About PLx Pharma (NASDAQ:PLXP) Stock

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Stock News Headlines

PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
PLx Pharma down after Q3 revenue fell 94% Y/Y
Earnings Preview: PLx Pharma
PLXP Aug 2022 5.000 call
PLx Pharma downgraded at Oppenheimer after Q2 miss
PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%
A Preview Of PLx Pharma's Earnings
PLXP PLx Pharma Inc.
See More Headlines
Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Company Calendar

Last Earnings
11/12/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/10/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLXP
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+3,328.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-46,130,000.00
Net Margins
-606.91%
Pretax Margin
-606.91%

Debt

Sales & Book Value

Annual Sales
$8.21 million
Book Value
$0.35 per share

Miscellaneous

Free Float
26,530,000
Market Cap
$10.20 million
Optionable
Not Optionable
Beta
3.73

Key Executives

  • Mr. Michael J. ValentinoMr. Michael J. Valentino (Age 68)
    Exec. Chairman
    Comp: $393.75k
  • Ms. Natasha Giordano (Age 62)
    CEO, Pres & Director
    Comp: $884.88k
  • Ms. Rita M. O'Connor CPA (Age 54)
    CPA, CFO and Head of Manufacturing & Supply Chain
    Comp: $623.23k
  • Mr. Ronald R. Zimmerman (Age 69)
    Founder & Sr. Advisor
  • Mr. Tom Long
    VP of Manufacturing & Technical Operations
  • Ms. Janet M. Barth
    VP of Investor Relations & Corp. Communications
  • Ms. Joanne Cotignola
    VP of Marketing
  • Mr. Patrick M. Lonergan (Age 87)
    Member of Chief Exec. Officer Advisory Group
  • Mr. Charles Edmund Sheedy C.F.A. (Age 75)
    CFA, Member of Chief Exec. Officer Advisory Group
  • Mr. Harris Kaplan M.B.A. (Age 70)
    MBA, Member of Chief Exec. Officer Advisory Group













PLXP Stock - Frequently Asked Questions

Should I buy or sell PLx Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PLXP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXP, but not buy additional shares or sell existing shares.
View PLXP analyst ratings
or view top-rated stocks.

What is PLx Pharma's stock price forecast for 2023?

3 analysts have issued 1-year target prices for PLx Pharma's stock. Their PLXP share price forecasts range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 3,328.6% from the stock's current price.
View analysts price targets for PLXP
or view top-rated stocks among Wall Street analysts.

How have PLXP shares performed in 2022?

PLx Pharma's stock was trading at $8.01 on January 1st, 2022. Since then, PLXP stock has decreased by 95.6% and is now trading at $0.35.
View the best growth stocks for 2022 here
.

When is PLx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023.
View our PLXP earnings forecast
.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) posted its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. The biotechnology company had revenue of $6.60 million for the quarter, compared to analysts' expectations of $4.10 million. PLx Pharma had a negative trailing twelve-month return on equity of 291.11% and a negative net margin of 606.91%. PLx Pharma's revenue for the quarter was up 560.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.40) EPS.

What other stocks do shareholders of PLx Pharma own?
When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Advisers LP (0.70%), Green Square Capital Advisors LLC (0.66%), University of Texas Texas AM Investment Managment Co. (0.43%), Shufro Rose & Co. LLC (0.28%), O Brien Greene & Co. Inc (0.23%) and Two Sigma Investments LP (0.20%). Insiders that own company stock include John Hadden, Michael J Valentino, Natasha Giordano and Rita M O'connor.
View institutional ownership trends
.

How do I buy shares of PLx Pharma?

Shares of PLXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $0.35.

How much money does PLx Pharma make?

PLx Pharma (NASDAQ:PLXP) has a market capitalization of $10.20 million and generates $8.21 million in revenue each year. The biotechnology company earns $-46,130,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The official website for the company is www.plxpharma.com. The biotechnology company can be reached via phone at (973) 409-6541, via email at lwilson@insitecony.com, or via fax at 713-842-3052.

This page (NASDAQ:PLXP) was last updated on 11/27/2022 by MarketBeat.com Staff